Evidence-based Complementary Oncology. Innovative Approaches to Optimize Standard Therapy Strategies
University of Cologne, Institute for Naturopathy, Joseph-Stelzmann-Strasse 9, 50931 Cologne, Germany.In vivo (Athens, Greece) (Impact Factor: 0.97). 03/2007; 21(2):423-8.
Cancer diseases demand diagnostic and therapeutic measures with proven quality, safety and efficacy. The basis for evaluation is clinical studies representing levels I or II (randomized controlled trials (RCT) or epidemiological cohort studies) in accordance with recommendations of the Centre for Evidence-based Medicine, University of Oxford, UK Regarding these claims, surgery, chemo-, radio- and hormone therapy have emerged as the gold standard in the treatment of carcinomas. These therapies have proven their cancer destructive potencies and their curative feasibilities, dependent on the particular cancer entity and stage. Complementary therapies are recommended to support and optimize the scientifically-based cancer standard treatment. Complementary medicine is currently widely debated by the oncological community, because the required scientific proof of safety and effectiveness for most of the therapeutic approaches has not yet been definitively provided. In the past years, basic research and clinical evaluation of defined complementary therapeutic concepts in oncology have been intensified in an attempt to integrate these procedures into evidence-based medicine. Scientifically-based therapies of complementary medicine cannot replace the well studied conventional cancer-destructive therapies such as surgery, chemo-, radio- or hormone therapy. Accordingly, they are by no means "alternative therapies". Complementary approaches in oncology that are recommended as additional to standard cancer destructive therapies claim to optimize this therapy. A great body of data emerging from scientifically sound clinical trials prove that defined complementary procedures are beneficial for the patients.
Full-text previewDOI: · Available from: iv.iiarjournals.org
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
[Show abstract] [Hide abstract]
- "Constitutively activated Bcr-Abl tyrosine kinase plays a critical role in the pathogenesis of CML and therapeutic resistance (Daley and Baltimore, 1988; Lugo et al., 1990; Sattler and Salgia, 1997). In order to reduce side effects and improve effectiveness of standard therapeutics, many complementary or alternative medicines (CAMs) have been tested so far with differing effectiveness (Beuth and Schierholz, 2007; Marvibaigi et al., 2014; Son et al., 2010). The aim of this study was to investigate possible additive antitumor activity of VAE with doxorubicin (Dox) and gain insight into molecular processes underlining these effects. "
ABSTRACT: Toxicity of conventional chemotherapeutics highlights the requirement for complementary or alternative medicines that would reduce side effects and improve their anticancer effectiveness. European mistletoe (Viscum album) has long been used as a complementary and alternative medicine supporting cancer therapy. The aim of this study was to investigate synergistic antitumor action of V. album extract and doxorubicin during co-treatment of chemoresistant chronic myelogenic leukemia K562 cells. Combined treatment of leukemia cells led to inhibitory synergism at sub-apoptotic doxorubicin concentrations and multifold reduction of cytotoxic effects in healthy control cells. Prolonged co-treatment was associated with reduced G2/M accumulation and increased expression of early and late apoptotic markers. Our data indicate that V. album extract increases antileukemic effectiveness of doxorubicin against resistant K562 cells by preventing G2/M arrest and inducing apoptosis. Copyright © 2015 John Wiley & Sons, Ltd.
- [Show abstract] [Hide abstract]
ABSTRACT: There is no evidence that selenium supplements reduce side effects of chemotherapy, radiotherapy or the effects of surgery in cancer patients. Selenium is a mineral necessary for human health. Selenium acts against cell damage in the body and might help to alleviate the side effects of therapies in cancer patients, such as nausea, diarrhoea or the lymph retention in limbs. Selenium supplements are frequently used by cancer patients. This systematic review looked at studies providing selenium supplements to cancer patients and found no clear evidence that selenium supplements improve side effects of cancer therapy. No adverse effects were reported in the studies, but evidence of overdosing, all be it unintentional and selenium intoxication has occurred in several selenium users. More research is needed to find out which doses of selenium supplements can be reasonably used by cancer patients and whether selenium supplements can affect the side effects of cancer therapy.
- [Show abstract] [Hide abstract]
ABSTRACT: The interpretation of medical images by radiologists is primarily and fundamentally a subjective activity, but there are a number of clinical applications such as tumor imaging where quantitative imaging (QI) metrics (such as tumor growth rate) would be valuable to the patient's care. It is predicted that the subjective interpretive environment of the past will, over the next decade, evolve toward the increased use of quantitative metrics for evaluating patient health from images. The increasing sophistication and resolution of modern tomographic scanners promote the development of meaningful quantitative end points, determined from images which are in turn produced using well-controlled imaging protocols. For the QI environment to expand, medical physicists, physicians, other researchers and equipment vendors need to work collaboratively to develop the quantitative protocols for imaging, scanner calibrations, and robust analytical software that will lead to the routine inclusion of quantitative parameters in the diagnosis and therapeutic assessment of human health. Most importantly, quantitative metrics need to be developed which have genuine impact on patient diagnosis and welfare, and only then will QI techniques become integrated into the clinical environment.